 Home > Medical News > Medical World News > The main report of "Building China's Pharmaceutical Innovation Ecosystem (2021-2025)" was officially released to assist

The main report of "Building China's Pharmaceutical Innovation Ecosystem (2021-2025)" was officially released to assist

 Last Update: 2021-11-12
 Source: Internet
 Author: User

Tags

what role nadh metabolism

transformation protein review

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Beijing, October 29, 2021, the launch of the report ``Building China's Pharmaceutical Innovation Ecosystem (2021-2025)'' was held in Beijing.

During the "Thirteenth Five-Year Plan" period, the construction of China's pharmaceutical innovation ecosystem has undergone a major historical turning point.

In response to the requirements of the times, the China Pharmaceutical Promotion Council and RDPAC started in early 2021, and organized and wrote 4 reports, focusing on "2015-2020 development review and future prospects", "promoting basic research, activating the source of innovation", and "multi-level medical care".

According to the press conference, in the past five years, China has built a vital pharmaceutical innovation industry with the advanced concepts of the innovation ecosystem, the top-level design vigorously promoted from top to bottom, and the fair competition and highly integrated innovative enterprises

Activate the source of innovation, and build a system and ability to transform basic research into industry

Realize synchronous research and development, improve the scientific nature of registration supervision and the efficiency of clinical research

To meet the needs of accessibility, we will construct a multi-level payment guarantee network

Guide innovative thinking and pay attention to the core orientation of clinical value

China's pharmaceutical industry is facing a great opportunity to move towards high-quality development by leaps and bounds.

(Song Ruilin, Executive Chairman of China Pharmaceutical Innovation Promotion Association)

Song Ruilin, executive chairman of the China Association for the Promotion of Pharmaceutical Products, said: "At present, a new round of scientific and technological revolution and industrial transformation are in-depth development.

(Conway, Executive President, Pharmaceutical Research and Development Industry Committee (RDPAC), China Association of Enterprises with Foreign Investment)

Conway, CEO of RDPAC, said: "The series of research reports on "Building China's Pharmaceutical Innovation Ecosystem" lasted for nearly a year and gathered support and contributions from multiple sources at home and abroad.

About China Pharmaceutical Innovation Promotion AssociationAbout China Pharmaceutical Innovation Promotion Association

China Pharmaceutical Innovation Promotion Association (hereinafter referred to as China Pharmaceutical Promotion Association) was established in 1988 and is a non-profit national 4A social organization registered by the Ministry of Civil Affairs

About the Pharmaceutical Research and Development Committee of the China Association of Enterprises with Foreign InvestmentAbout the Pharmaceutical Research and Development Committee of China Association of Enterprises with Foreign Investment

The Pharmaceutical Research and Development Industry Committee of the China Association of Enterprises with Foreign Investment (RDPAC) is a non-profit organization composed of 45 multinational pharmaceutical companies with research and development capabilities.
It was established in 1999 and belongs to the "China Association of Enterprises with Foreign Investment"
.
As of June 2020, RDPAC member companies have established 47 factories and 25 R&D centers in Mainland China
.
RDPAC members share the same aspiration with the Chinese government and local pharmaceutical companies, that is, hope that China will become a major country in pharmaceutical innovation
.
RDPAC looks forward to having the opportunity to work together with the Chinese government and develop in coordination to realize this wish and enable innovative drugs to benefit more Chinese and global patients
.

Click on the link below to get the full report:

Click the link below to get the full report: Click the link below to get the full report:

"Building China's Pharmaceutical Innovation Ecosystem (2021-2025)"

"Building China's Pharmaceutical Innovation Ecosystem (2021-2025)" "Building China's Pharmaceutical Innovation Ecosystem (2021-2025)"

http://cnadmin.
rdpac.
org/upload/upload_file/1635401825.
pdf

Click the link below to get the published series of reports:

Click the following link to get the published series report: Click the following link to get the published series report:

"Building China's Pharmaceutical Innovation Ecosystem-Part One of a Series Report: 2015-2020 Development Review and Future Prospects"

"Building China's Pharmaceutical Innovation Ecosystem-Part One of the Series Report: 2015-2020 Development Review and Future Prospects" "Building China's Pharmaceutical Innovation Ecosystem-Part One of the Series Report: 2015-2020 Development Review and Future Prospects"

http://cnadmin.
rdpac.
org/upload/upload_file/1614646546.
pdf

"Building China's Pharmaceutical Innovation Ecosystem-Part Two of the Series: Promoting Basic Research and Activating the Source of Innovation"

"Building China's Pharmaceutical Innovation Ecosystem-Part Two of the Report Series: Promoting Basic Research and Activating the Source of Innovation" "Building China's Pharmaceutical Innovation Ecosystem-Part Two of the Series Report: Promoting Basic Research and Activating the Source of Innovation"

http://cnadmin.
rdpac.
org/upload/upload_file/1623319560.
pdf

"Building China's Pharmaceutical Innovation Ecosystem-Part Three of the Series: Multi-level Medical Security System Boosts People's Health and High-quality Industrial Development"

"Building China's Pharmaceutical Innovation Ecosystem-Part Three of the Series: Multi-level Medical Security System Boosts People's Health and High-quality Industry Development" "Building China's Pharmaceutical Innovation Ecosystem-Part Three of the Series Report: Multi-level Medical Security System Help People's health and high-quality development of industry"

http://cnadmin.
rdpac.
org/upload/upload_file/1629074320.
pdf

"Building China's Pharmaceutical Innovation Ecosystem Series Report Fourth: Promoting the Synchronous R&D, Registration and Evaluation of Innovative Drugs"

"Building China's Pharmaceutical Innovation Ecosystem Series Report Fourth: Promoting the Synchronous R&D, Registration and Review of Innovative Drugs" "Building China's Pharmaceutical Innovation Ecosystem Series Report Fourth: Promoting the Simultaneous R&D, Registration and Review of Innovative Drugs"

http://cnadmin.
rdpac.
org/upload/upload_file/1631519479.
pdf

http://cnadmin.
rdpac.
org/upload/upload_file/1631519479.
pdf
SF Express helps the new development of the pharmaceutical supply chain
Ronglian debuts at ICG-16, driving precision medicine and clinical research innovation with big data + AI

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.